— Know what they know.
Not Investment Advice
Also trades as: 0K16.L (LSE) · $vol 0M

EOLS NASDAQ

Evolus, Inc.
1W: -2.0% 1M: +24.3% 3M: +47.6% YTD: -4.0% 1Y: -35.2% 3Y: -33.6% 5Y: -28.8%
$6.09
-0.36 (-5.58%)
 
Weekly Expected Move ±9.3%
$5 $6 $6 $7 $8
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Buy · Power 63 · $401.1M mcap · 50M float · 2.26% daily turnover · Short 28% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$297M +11.6% ▲
5Y CAGR: +39.4%
Gross Profit
$193M +5.7% ▲
5Y CAGR: +38.2%
Operating Income
-$38M -9.3% ▼
Net Income
-$52M -2.4% ▼
EPS (Diluted)
$-0.80 +1.2% ▲
EBITDA
-$29M -15.4% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$100M$149M$202M$266M$297M
YoY Growth+76.3%+49.1%+36.0%+31.8%+11.6%
Cost of Revenue$44M$59M$62M$84M$104M
Gross Profit$56M$90M$141M$182M$193M
Gross Margin56.3%60.4%69.5%68.5%64.9%
R&D Expenses$2M$7M$15M$9M$10M
SG&A Expenses$112M$142M$165M$198M$221M
Operating Expenses$101M$155M$190M$217M$230M
Operating Income-$44M-$65M-$49M-$34M-$38M
Operating Margin-44.6%-44.0%-24.4%-12.9%-12.7%
Interest Expense$1M$9M$14M$19M$20M
Income Before Tax-$47M-$74M-$62M-$50M-$51M
Tax Expense$42K$95K$176K$664K$677K
Net Income-$47M-$74M-$62M-$50M-$52M
Net Margin-47.0%-50.1%-30.5%-18.9%-17.4%
EPS (Diluted)$-0.94$-1.33$-1.08$-0.81$-0.80
EBITDA-$39M-$54M-$42M-$25M-$29M
Shares Outstanding50M56M57M62M64M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms